Wire · operational-macro
Retatrutide results: weight loss, side effects, cost, and access
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 October 2026 · Fusion42 review
Eli Lilly's experimental obesity drug retatrutide showed substantial weight loss in trials but is not yet FDA approved, with cost and side effects being major barriers to sustained use. The drugmakers have shifted to direct-to-consumer cash sales, positioning obesity treatment as a subscription-like model, while insurers and state Medicaid programs limit coverage.
This Wire brief sits within Fusion42's coverage of Health, and 2 sources have reported it between 30 Sep 2026 and 1 Oct 2026.
◆ ◆ The Wire takeaway
You face a cost barrier as insurers pull back obesity drug coverage, making direct cash sales your main customer route. This changes the business model from insurer reimbursement to subscription-style consumer sales.
◆ Coverage
2 sources · first reported 30 Sep 2026 · latest 1 Oct 2026
◆ Related on Wire
◆ Topics